We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novartis has released new data from a late-stage study showing that its multiple sclerosis (MS) drug Kesimpta (ofatumumab) reduced the risk of disease progression. Read More
In an unusual move for a pharma company, New Jersey-based Pacira Biosciences has filed a libel lawsuit against the American Society of Anesthesiologists over several articles published in the society’s medical journal, charging the organization with unfairly disparaging its nonopioid painkiller Exparel. Read More
A bench trial in a 2019 lawsuit by Ferring Pharmaceuticals against generic drug giant Lupin Pharmaceuticals gets under way today, with Ferring alleging that the generic drugmaker sought to infringe on a patent for its prescription drug Clenpiq, a drinkable bowel cleanser. Read More
The FDA has approved Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) in combination with chemotherapy as a first-line treatment for patients with gastric and esophageal cancers. Read More
The Biden administration announced Friday that it is dedicating $1.7 billion in funding from the COVID-19 relief package to ramp up U.S. capabilities for genomic sequencing, an effort to improve the ability of the Centers for Disease Control and Prevention (CDC) and the nation’s health departments to detect potentially deadly mutations. Read More
The Centers for Disease Control and Prevention (CDC) will convene a second emergency meeting of its Advisory Committee on Immunization Practices at the end of the week to discuss the use of Johnson & Johnson (J&J)’s COVID-19 vaccine, following a delayed vote at its initial discussion on cases of very rare blood clots seen in vaccinated patients. Read More
Novartis has agreed to help manufacture Roche’s blockbuster rheumatoid arthritis drug Actemra (tocilizumab) as a COVID-19 treatment — in another pact that offers the company’s manufacturing might to help produce a rival’s COVID-19 therapies or vaccines. Read More
A potential new treatment for a severe form of Type 1 diabetes received a boost Thursday when the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted 12-4, with one abstention, that the benefits of the therapy outweigh its risks. Read More